<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002352</url>
  </required_header>
  <id_info>
    <org_study_id>248A</org_study_id>
    <secondary_id>AI459-007</secondary_id>
    <nct_id>NCT00002352</nct_id>
  </id_info>
  <brief_title>A Study of Lobucavir in Patients With AIDS</brief_title>
  <official_title>Pilot Study of the Antiviral Activity of Multiple Doses of Oral Lobucavir in AIDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if lobucavir is a safe and effective treatment for
      cytomegalovirus in patients with AIDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive 1 of 2 doses of lobucavir for 28 days, with 2 weeks of follow-up. Weekly
      clinic visits are required.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>30</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lobucavir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Aerosolized pentamidine.

          -  TMP / SMX.

          -  Isoniazid.

          -  Dapsone.

          -  Fluconazole.

          -  Ketoconazole.

          -  Rifabutin.

          -  Fluoxetine HCl.

          -  Acetaminophen.

          -  Antacids.

          -  Metamucil.

          -  Multivitamins.

          -  Other drugs with approval from sponsor.

        Patients must have:

          -  AIDS.

          -  CD4 count &lt; 200 cells/mm3.

          -  Cytomegalovirus ( CMV ) viruria and virosemenia.

          -  No evidence of intraocular CMV.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following symptoms or conditions are excluded:

          -  Acute or chronic cardiovascular, pulmonary, renal, hepatic, pancreatic, hematologic,
             endocrine, neurological, or other unstable illness.

          -  Inability to take oral medication.

          -  Allergy to nucleoside analogs.

          -  Diarrheal illness.

          -  Poor venous access.

          -  Positive test for drugs of abuse.

          -  Any other condition that would render patient unsuitable for study.

        Patients with the following prior conditions are excluded:

          -  History of pancreatitis.

          -  Recent diarrheal illness.

          -  History of weight loss.

          -  Acute serious illness within 4 weeks prior to study entry.

        Prior Medication:

        Excluded within 4 weeks prior to study entry:

          -  Erythropoietin.

          -  Any agent with anti-CMV activity.

          -  Other investigational agents.

        Prior Treatment:

        Excluded within 4 weeks prior to study entry:

          -  Surgery.

          -  Blood transfusion. Drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mount Zion Med Ctr / UCSF</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Veterans Adm Med Cntr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>October 1, 2007</last_update_submitted>
  <last_update_submitted_qc>October 1, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2007</last_update_posted>
  <keyword>Cytomegalovirus Infections</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>Antiviral Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lobucavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

